APREX · EST. 2026
OpenAI has announced the launch of Rosalind Biodefense, a new program that expands access to the specialized AI model GPT-Rosalind. Access is reserved for verified developers and selected US government partners working on biodefense, public health, and pandemic preparedness. OpenAI reports this on its official website.
The naming is a tribute to Rosalind Franklin, the British chemist whose X-ray crystallography was crucial to the discovery of the DNA structure.
What is GPT-Rosalind?
GPT-Rosalind is a customized version of OpenAI's frontier models, developed for use in biomedical and security-critical contexts. According to OpenAI, the program is designed to support everything from infectious disease surveillance to research on countermeasures against biological threats.
Access is not open to everyone: actors must go through an approval process before they can use the model. This type of controlled access is justified by the sensitive nature of the field – biological information can be misused if it falls into the wrong hands.
A rapidly growing market
The launch comes in a market where governmental and private actors worldwide are significantly increasing their investments. According to market analyses, the global biodefense market is valued at between 17.3 and 18.2 billion USD in 2024 – depending on the analysis model used. The USA dominates with a share of nearly 43 percent of the global market, and the American segment alone is estimated at 13.8 billion USD.
Growth is driven by increased biological threat levels, larger public budgets, and a shift from reactive to proactive defense strategies – where AI is a central tool.
AI's role in biodefense
Artificial intelligence is now used at several levels in biodefense. Early disease surveillance is a key area: AI systems can integrate data from hospitals, environmental sensors, genome databases, and social media to detect unusual disease patterns and quickly alert health authorities.
In vaccine and drug development, AI models analyze molecular structures and predict how pathogens interact with the immune system – which can accelerate the work of developing countermeasures. AI is also used for bioforensics, rapid identification of pathogens during biological incidents, and to protect genome databases and laboratory networks from cyberattacks.
Governments pump in funds
It's not just the private sector that is investing. The US Department of Defense requested 1.8 billion USD for AI-specific research in 2024 – more than double the amount from 2023. On the EU side, the EU Defense Fund has allocated 1.2 billion euros for collaborative defense projects that integrate AI systems, according to market data collected for this article.
The dominant players in the biodefense market are a mix of large pharmaceutical companies, defense contractors, and specialized biotechnology companies. Boeing and Lockheed Martin are among those integrating AI-driven analysis into biological threat detection systems. In April 2025, Parsons Corporation was awarded a contract to improve research on rapid detection of infectious diseases.
Limited insight gives reason to read carefully
It is worth noting that OpenAI's announcement is concise and largely relies on its own formulations about “frontier AI” and “trusted access.” Independent assessment of GPT-Rosalind's actual capabilities, any security protocols, and the extent of government collaboration is currently unavailable. Technology companies launching security-oriented products in collaboration with authorities often communicate limited details for obvious security reasons – but this also makes it difficult to assess the weight of the claims.
The biodefense field is nevertheless one of the most concrete and well-documented examples of AI investment with real societal benefit – and OpenAI's entry marks that the major AI laboratories are now positioning themselves heavily in this space.